FOOT & ANKLE
COA: Use of rhPDGF in a collagen matrix effective for foot and ankle fusion
217 patients undergoing hindfoot and ankle reconstruction were randomized to receive either the Augment Injectable Bone Graft, containing platelet-derived growth factor (rhPDGF-BB in a tricalcium phosphate (B-TCP)/collagen matrix, or an autogenous bone graft to compare bone fusion and clinical success rates. Patients were to be assessed over a 1 year period; preliminary results indicated that fusion and clinical success rates were significantly higher in the group of patients who received rhPDF-BB in a collagen matrix during surgery, compared to patients who received the autogenous bone graft.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
